Antipsychotic: Difference between revisions
>Oskykins No edit summary |
>Oskykins No edit summary |
||
Line 2: | Line 2: | ||
'''Antipsychotics''' (also known as '''neuroleptics''' or '''major tranquilizers''')<ref>http://books.google.ca/books?id=Q4hG2gRhy7oC&pg=PA151</ref> are a class of psychiatric medication primarily used to manage [[psychosis]] (including [[Delusions|delusions]], hallucinations, or disordered thought), particularly in [[schizophrenia]] and bipolar disorder. | '''Antipsychotics''' (also known as '''neuroleptics''' or '''major tranquilizers''')<ref>http://books.google.ca/books?id=Q4hG2gRhy7oC&pg=PA151</ref> are a class of psychiatric medication primarily used to manage [[psychosis]] (including [[Delusions|delusions]], hallucinations, or disordered thought), particularly in [[schizophrenia]] and bipolar disorder. | ||
First generation antipsychotics, known as typical antipsychotics, were discovered in the 1950s. Most second generation drugs, | First generation antipsychotics, known as typical antipsychotics, were discovered in the 1950s. Most second generation drugs, called atypical antipsychotics, have been developed more recently. The first atypical antipsychotic, [[clozapine]], was discovered in the 1950s and introduced clinically in the 1970s. Both generations of medication tend to block receptors in the brain's [[dopamine]] pathways but atypicals tend to act on [[serotonin]] receptors as well. | ||
Notable and relatively common adverse effects of antipsychotics include extrapyramidal symptoms (which involve motor control), hyperprolactinaemia (primarily in typicals), weight gain and metabolic abnormalities (mostly in atypicals).<ref name = "SCZ">{{cite web | url = http://emedicine.medscape.com/article/288259-overview | title = Schizophrenia | author = Frankenburg FR, Dunayevich E, Albucher RC, Talavera F | publisher = emedicine.medscape.com | accessdate = 2013-10-02 }}</ref> | Notable and relatively common adverse effects of antipsychotics include extrapyramidal symptoms (which involve motor control), hyperprolactinaemia (primarily in typicals), weight gain and metabolic abnormalities (mostly in atypicals).<ref name = "SCZ">{{cite web | url = http://emedicine.medscape.com/article/288259-overview | title = Schizophrenia | author = Frankenburg FR, Dunayevich E, Albucher RC, Talavera F | publisher = emedicine.medscape.com | accessdate = 2013-10-02 }}</ref> |